Alpha-Synuclein Mediated Hyperphosphorylation of Tau in the Genesis of Neurodegenerative Diseases
Section: For Industry
Categories: "Neurodegenerative Therapeutics"
Reference #: 2007-027
OTC Contact: David Humphrey (Directory Information | Send a Message)
Description
Georgetown University researchers have shown that alpha-synuclein hyperphosphorylates Tau, through the direct activation of at least two kinases, GSK-3beta and ERK. This is the first time that hyperphosphorylated Tau has been linked to the genesis of Parkinson's disease and synucleopathies. Thus, blockade of the hyperphosphorylation of Tau will be a viable treatment strategy to prevent ongoing neurodegeneration of different brain regions.
Applications
Early stage diagnostic as well as potential treatment of Parkinson’s disease.
Advantages
Stage of Development
Animal studies testing the hypothesis that reducing alpha-synuclein levels or blockade of kinases that hyperphosphorylate Tau, will prevent the degeneration of the nigrostriatal system in toxin models, and will cause arrest or reversal of degenerated neurons are underway.Relevant Publications
Duka et al. Alpha-Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism. FASEB Journal 20: 2302-2312 2006.
Inventor: Dr. Anita Sidhu
Patent Status
U.S. and Foreign Rights protected.
